CellinCells

About CellinCells

CellinCells, a South Korean biotechnology firm founded in 2014, is focused on developing organoid-based regenerative therapeutics. The company's core asset is its proprietary Tissue Reforming Technology Platform (TRTP), a system designed to create high-quality organoid tissue modules by leveraging the self-organization capabilities of cells. This technology addresses key challenges in the field—such as size limitations, control, and reproducibility—by using a unique concave, cup-shaped structure for manufacturing organoid-tissue modules, which facilitates better nutrient and oxygen supply without artificial scaffolds.

The company's business strategy revolves around several key areas, including the out-licensing of its pipeline products, sharing its organoid platform technology, and expanding its organoid and stem cell technology business. CellinCells' revenue model is structured around these partnerships and licensing agreements. The company has successfully raised $13.8M in funding, with investors including KB Investment, JX Partners, and Ulmus Investment.

The primary pipeline product, TRTP-101, is a skin regenerative therapy for treating atrophic scars. In August 2023, CellinCells received Investigational New Drug (IND) approval in South Korea for TRTP-101, a first for an organoid-based therapy in the country. The company completed patient dosing for the Phase 1 clinical trial in 2024 and expects to report clinical results in the first quarter of 2025. Other pipeline products target cartilage defects, osteoarthritis, and the development of organoid-derived medical materials like pure human ECM and exosomes. The company is also exploring applications for arthritis, meniscus injuries, and frozen shoulder. To support its manufacturing needs, CellinCells has entered into a Contract Development and Manufacturing Organization (CDMO) agreement with ENCell for the production of clinical trial materials.